Beyond Topicals: From Skin to System – Exploring the New Oral Era in Psoriasis & Melasma

Abstract

Psoriasis and melasma are chronic dermatological conditions with significant psychosocial and physical morbidity, traditionally managed by topical agents. However, advancements in systemic therapies, particularly oral agents, have revolutionized management strategies, moving beyond mere symptomatic relief to targeted pathophysiological modulation. This review synthesizes recent clinical evidence, guideline recommendations, and mechanistic insights into the evolving role of oral therapies in both conditions, providing a comprehensive resource for clinicians navigating the new therapeutic landscape.

Introduction

Psoriasis and melasma represent two distinct yet impactful dermatological disorders. While psoriasis is an immune-mediated inflammatory disease with systemic implications, melasma is a chronic pigmentary disorder primarily affecting facial skin. Both conditions disproportionately affect quality of life, and their management has long relied on topical approaches. With deeper understanding of disease mechanisms, a paradigm shift towards systemic and especially oral interventions is underway. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, and evolving treatment strategies, emphasizing the emergence of oral therapies and their clinical relevance.

Epidemiology / Disease Burden

Psoriasis affects approximately 2–3% of the global population, with variable prevalence across different ethnicities and geographic regions. It is associated with substantial comorbidity, including psoriatic arthritis, metabolic syndrome, and cardiovascular disease. Melasma, although less life-threatening, imposes a significant psychosocial burden, especially among women of reproductive age in regions with high UV exposure. The prevalence of melasma ranges from 1.5% to 33% depending on population studies, with higher incidence in Fitzpatrick skin types IV–VI. Both conditions are chronic, relapsing, and frequently resistant to monotherapy, necessitating long-term, multifaceted management approaches.

Pathophysiology

Psoriasis is characterized by dysregulated immune activation, involving an interplay between keratinocytes, dendritic cells, and T lymphocytes, notably Th17 and Th1 pathways. Key cytokines such as TNF-α, IL-17, and IL-23 drive the inflammatory cascade, resulting in keratinocyte hyperproliferation and plaque formation. Melasma pathogenesis is multifactorial, involving melanocyte hyperactivity, hormonal influences (particularly estrogen and progesterone), genetic predisposition, and ultraviolet radiation-induced oxidative stress. Recent evidence implicates vascular, inflammatory, and dermal factors beyond melanogenesis, supporting the rationale for systemic interventions.

Risk Factors

For psoriasis, identified risk factors include genetic susceptibility (notably HLA-Cw6), environmental triggers (infections, stress, trauma), smoking, obesity, and certain medications (lithium, beta-blockers). Melasma risk is strongly associated with UV exposure, hormonal fluctuations (pregnancy, oral contraceptives), family history, and phototoxic drugs. In both diseases, chronicity and relapse are influenced by ongoing exposure to these risk factors, underscoring the importance of comprehensive risk assessment in clinical practice.

Clinical Features

Psoriasis clinically manifests as well-demarcated erythematous plaques with silvery scale, commonly affecting extensor surfaces, scalp, and lumbosacral areas. Variants include guttate, inverse, pustular, and erythrodermic psoriasis. Pruritus, pain, and nail involvement are frequent, and up to 30% of patients develop psoriatic arthritis. Melasma presents as symmetric, hyperpigmented macules and patches, predominantly on the malar, centrofacial, or mandibular regions. The diagnosis is clinical but may be supplemented by Wood’s lamp examination and dermoscopy to distinguish epidermal from dermal involvement.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by histopathology in atypical cases. Severity is assessed with tools such as the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI). Melasma diagnosis is clinical, with adjunctive techniques like reflectance confocal microscopy, colorimetry, and biopsies in refractory or atypical presentations. Proper evaluation ensures accurate classification and guides therapeutic decision-making.

Treatment & Management

Topical corticosteroids, vitamin D analogues, and calcineurin inhibitors remain first-line for mild psoriasis, with phototherapy and systemic agents reserved for moderate-to-severe disease. Conventional oral agents include methotrexate, cyclosporine, and acitretin, but newer oral therapies—such as apremilast (a PDE4 inhibitor) and Janus kinase (JAK) inhibitors—offer improved efficacy and safety profiles. In melasma, topical hydroquinone, retinoids, and triple combinations are mainstays, but oral agents like tranexamic acid, antioxidants (polypodium leucotomos, glutathione), and even hormonal modulators are gaining traction for refractory cases. Systemic therapy selection is guided by disease severity, comorbidities, and patient preferences.

Recent Advances / Emerging Therapies

The recent introduction of targeted oral therapies has transformed the therapeutic landscape. For psoriasis, apremilast demonstrates moderate efficacy with favorable tolerability, while JAK inhibitors (such as tofacitinib, deucravacitinib) are under active investigation for both cutaneous and articular symptoms. In melasma, oral tranexamic acid (TA) has shown promising results in reducing pigmentation by inhibiting plasminogen activation and subsequent melanogenesis. Emerging data suggest that combining oral agents with topical and procedural modalities yields superior outcomes, although long-term safety monitoring is essential. Advances in pharmacogenomics and personalized medicine hold promise for optimizing systemic therapy in both conditions.

Guideline Recommendations

International guidelines increasingly recognize the role of systemic and oral agents in moderate-to-severe psoriasis and refractory melasma. The American Academy of Dermatology and European Dermatology Forum advocate for individualized therapy based on disease severity, comorbidities, and prior treatment response. For melasma, consensus statements support oral tranexamic acid as an adjunct in recalcitrant cases, with caution regarding thromboembolic risk. Shared decision-making and vigilant monitoring are emphasized to balance efficacy and safety.

Conclusion

The management of psoriasis and melasma is evolving from surface-level interventions to mechanism-based systemic therapies. Oral agents offer new opportunities for durable disease control, especially in patients unresponsive to topicals. Clinicians must integrate recent evidence, guideline recommendations, and patient-centered considerations to optimize outcomes. Continued research, pharmacovigilance, and education are essential to realize the full potential of the oral era in dermatology.